期刊文献+

PPARγ激动剂吡格列酮对大鼠脑缺血再灌注损伤的作用研究 被引量:1

Effects of peroxisome proliferator activated receptorγPioglitazone on cerebral ischemic injury in rats
暂未订购
导出
摘要 目的:研究过氧化物酶体增生物激活受体γ(PPARγ)激动剂吡格列酮预处理对大鼠脑缺血再灌注损伤的影响,探讨PPARγ在脑缺血再灌注损伤中的作用。方法:选用健康SpragueDawley(SD)大鼠72只,随机分为假手术组、对照组和吡格列酮组。采用大鼠大脑中动脉闭塞2h再灌注模型,于缺血再灌注损伤后24h,进行神经功能缺陷评分监测神经功能缺损情况;通过2,3,5,-氯化三苯基四氮唑(TTC)染色测定脑梗死体积;通过干湿重法检测脑水含量;通过TUNEL方法,观察各实验组鼠脑缺血半暗带神经细胞的凋亡。结果 :与对照组相比,缺血再灌注损伤后24h吡格列酮组的神经功能缺陷评分(P<0.05)、脑梗死面积(P<0.05)、脑水含量(P<0.01)和缺血半暗带神经细胞凋亡(P<0.01)均明显低于对照组。结论:PPARγ激动剂吡格列酮对大鼠缺血再灌注脑损伤有明显的保护作用,抗凋亡作用可能是PPARγ发挥保护作用的机制之一。 Objective :To investigate the role of peroxisome proliferator activated receptor γ(PPARTγ)in cerebral ischemic injury by PPAR7 agonist pioglitazone treating in rats. Methods: One seventy-two Sprague-Dawley (SD) rats were randomly divided into sham group, middle cerebral artery occlusion (MCAO) group and pioglitazone treatment group. At 24h after ischemia reperfusion injury, neurological impairment was evaluated by neurological deficit score (NDS), infarct volume was measured by dUTP nick-end labeling 2,3,5, triphenyltetrazolium chlo- ride (TTC) staining, brain water content was measured by dry and wet weights of brain, and neuronal apoptosis in the ischemic brain tissue was assessed in situ by terminal deoxynucleotide transferase-mediated (TUNEL) staining at 24h after ischemic brain injury. Results :Compared with MCAO group rats, NDS(P〈0.05), infarct volume(P〈0. 05), brain water content(P〈0.01) and neuronal apoptosis(P〈0.01) in the ischemic brain tissue were significantly lower than those in GW501516 pretreatment group rats at 24h after ischemic brain injury, respectively. Conclusion: pioglitazone, a PPARyagonist, has a neuroprotective effect on ischemic brain injury in rats, and the antiapoptosis effect of pioglitazone may contribute to a beneficial effect against ischemic brain injury.
出处 《陕西医学杂志》 CAS 2013年第12期1574-1575,1580,共3页 Shaanxi Medical Journal
基金 陕西省自然科学基金(2010JM4032)
关键词 缺血 并发症 再灌注损伤 @过氧化物酶体增生物激活受体γ 动物 实验 大鼠 Ischemia/complications Reperfusion @PPARr Animals,laboratory Rats
  • 相关文献

参考文献6

  • 1Allahtavakol M, Shabanzadeh A, Roohbakhsh A, et al. Combination theapy of rosigIitazone, a peroxisome proI- iferators-activated receptor gamma [igand, and NMDA receptor antagonist (MK-801) on experimental embolic stroke in rats[J]. Basic CIin Pharmacol Toxicol, 2007, 101(5) ~ 309-314.
  • 2Kataoka Y, Yagi N, KokubLl N, et al. Effect of pre- treatment with pioglitazone on reperfusion injury in dia- betic patients with acute infarction [J]. Circ J, 2011,75(8):1968-1974.
  • 3王嫘,赵心,孟馨,陈思娇.罗格列酮对老年2型糖尿病患者颈动脉硬化的影响[J].陕西医学杂志,2011,40(4):441-442. 被引量:2
  • 4Culman J, Nguyen-Ngoc M, Glatz T, et aZ. Treatment of rats with pioglitazone in the reperfusion phase of focal cerebral ischemia:A preclinicalstroke trial [J] Exp Neu- rol, 2012,238(2)~ 243-253.
  • 5Michalik L, Desvergne B, Wahli W. Peroxisome-prolif- erator-activated receptors and cancers: Complex stories [J]. Nat Rev Cancer, 2004, 4:61 - 70.
  • 6雍芳,狄政莉.过氧化物酶体增殖物激活受体γ在中枢神经系统疾病中作用的研究进展[J].国际神经病学神经外科学杂志,2012,39(4):358-361. 被引量:1

二级参考文献32

  • 1罗洁,曹丽.酒石酸罗格列酮对2型糖尿病患者颈动脉内膜中层厚度作用的分析[J].天津医科大学学报,2006,12(1):62-64. 被引量:2
  • 2张妍,徐桂芳,程雯,徐婷,陈淑雯.罗格列酮对2型糖尿病患者颈动脉内膜厚度的影响[J].中国临床药理学杂志,2007,23(3):168-170. 被引量:3
  • 3Lorenz MW, Markus HS, Bots ML, et al. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis[J].irculation,2007, 115(4): 459-467.
  • 4Tunis SL, Minshall ME, St-Charles M, et al. Pioglitazone versus rosiglitazone treatment in patients with type 2 diabetes and dyslipidemia : cost-effectiveness in the US. [J]. Curt Med Res Opin, 2008,24(11): 3085-3096.
  • 5Lin KD, Chang YH, Wang CL, et al. Thiazolidinedione addition reduces the serum retinol-binding protein 4 in type 2 diabetic patients treated with metformin and sulfonylurea[J]. Transl Res, 2008, 151(6): 309-314.
  • 6Panunti B,Kunhiraman B,Fonseca V,et al. The impact of antidiabetic therapies on cardiovascular disease[J]. Curt Atheroscler Rep,2005, 7(1): 50-57.
  • 7Craft S, Watson GS. Insulin and neurodegenerative disease: shared and specific mechanisms. Lancet Neuro, 2004, 3 (3) : 169-178.
  • 8Gumell M. PPAR gamma and metabolism: insights from the study of human genetic variants. Clin Endocrinol, 2003 , 59 (3) : 267 -277.
  • 9Lee CH, Park OK, Yoo KY, et al. The role of peroxisome proliferator-activated receptor gamma, and effects of its ago- nist, rosiglitazone, on transient cerebral ischemic damage. J Neurosci, 2011 , 300(1-2) : 120-129.
  • 10Kaundal RK, Sharma SS. GW1929:a nonthiazolidinedione PPARgamma agonist, ameliorates neurological damage in glob- al cerebral ischemic-reperfusion injury through reduction in in- flammation and DNA fragmentation. Behav Brain Res, 20ll, 216(2) : 606-612.

共引文献1

同被引文献22

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部